SEARCH RESULT

Total Matching Records found : 219

Special drive for registration of cycle-rickshaws in Delhi -Mohammad Ali

-The Hindu   High Court has been hearing a petition by non-government organisation After years of harassment from the police and municipal authorities, there is finally some good news for the rickshaw pullers and owners. In compliance with the directions of the Delhi High Court, the East Delhi Municipal Corporation (EDMC) on Wednesday announced a special drive for registration of cycle-rickshaws and rickshaw pullers through their Citizen Service Bureaus (CSB). Likewise, the North...

More »

Glivec lesson for pharma: Patented drugs must be priced smartly-Kiran Mazumdar Shaw

-The Economic Times To ensure access to healthcare for all, India must harness innovation in discovering drugs, in developing therapeutics and in delivering affordable healthcare. It is in the light of these facts that one should evaluate the impact of the Indian Supreme Court's ruling in the case involving patent protection for Novartis AG's cancer drug, Glivec. Glivec was the first-of-its-kind cancer drug for leukaemia patients with patent protection in nearly 40...

More »

Novartis order may force pharma MNCs to change

-The Economic Times Foreign pharma companies could be forced to overhaul their strategy for the Indian market by striking more local deals and cutting sky-high drug prices after the Supreme Court slammed the door on Swiss giant Novartis' attempts to gain a patent for its blood cancer-busting drug Glivec. But the ruling, welcomed by activists campaigning for affordable drugs and local generic companies, threatened to reinforce a narrative that India...

More »

A just order

-The Hindu The Supreme Court order rejecting a plea to grant patent protection for Glivec, a cancer-fighting drug from Novartis, is a landmark. It will greatly strengthen the quest for access to affordable medicines in India. The decision affirms the idea that a patent regime loses its social relevance when a drug is priced beyond the reach of the vast majority of a country's people. That pharmaceutical companies employ high pricing...

More »

Novartis case may make foreign firms more wary of Indian drugs market-Ravi Ananthanarayanan

-Live Mint SC judgement may not open a floodgate of revenues for local pharma firms; nevertheless, it is a psychological win The Supreme Court has dismissed an appeal by Novartis AG to revoke denial of a patent to its cancer drug Glivec. The judgement is important because multinational companies (MNCs) can be denied patent protection on improved drugs unless they can prove the medication has better efficacy. Although this decision will displease...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close